Pulmonary Arterial Hypertension (PAH)

»Pulmonary Arterial Hypertension (PAH)
15 05, 2017

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

2017-05-15T14:39:47+00:00

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension - Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif., May 15, 2017 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of [...]

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 2017-05-15T14:39:47+00:00
4 05, 2017

Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City

2017-05-15T14:42:12+00:00

Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City - Phase 2 LIBERTY Study Update for Ubenimex in PAH PALO ALTO, Calif. – May 4, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development [...]

Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City 2017-05-15T14:42:12+00:00
3 01, 2017

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)

2017-02-07T16:31:04+00:00

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) — First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif., January 3, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced [...]

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) 2017-02-07T16:31:04+00:00
18 07, 2016

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

2017-02-07T17:40:25+00:00

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension Novel first-in-class inhibitor of LTB4 targeting disease modification PALO ALTO, Calif., July 18, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the [...]

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 2017-02-07T17:40:25+00:00
28 03, 2016

Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency

2017-02-07T18:24:52+00:00

Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency PALO ALTO, Calif., March 28, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:  EIGR) today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product status to ubenimex for the treatment of pulmonary arterial hypertension (PAH). "We are very pleased [...]

Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency 2017-02-07T18:24:52+00:00
15 12, 2015

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension

2017-02-07T18:40:46+00:00

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension PALO ALTO, Calif., December 15, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 13/839,321, entitled “Treatment [...]

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension 2017-02-07T18:40:46+00:00
30 11, 2015

Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension

2017-02-07T18:42:47+00:00

Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension PALO ALTO, Calif., November 30, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug status to ubenimex for the treatment of pulmonary arterial hypertension (PAH). "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and [...]

Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension 2017-02-07T18:42:47+00:00
10 11, 2015

Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University

2017-02-07T18:49:21+00:00

Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University Novel Target Identified as Potential Therapeutic Approach to PAH PALO ALTO, Calif., November 10, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to technology for targeting effects of leukotriene B4 (LTB4) to modulate [...]

Eiger Bio Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University 2017-02-07T18:49:21+00:00
9 11, 2015

Eiger Bio Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex)

2017-02-07T18:51:26+00:00

Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for Inflammatory Diseases Involving LTB4 First Clinical Target – Pulmonary Arterial Hypertension (PAH) PALO ALTO, Calif., November 9, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced a license agreement with Nippon Kayaku Co., Ltd., Tokyo, Japan, to develop Bestatin™ (ubenimex) for [...]

Eiger Bio Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) 2017-02-07T18:51:26+00:00